Who is sponsoring NCT02670434?

NCT02670434 is sponsored by Kowa Research Institute, Inc..

What condition does NCT02670434 study?

NCT02670434 studies Hyperlipidemia, Dyslipidemia.

What drugs are being tested in NCT02670434?

Interventions: NK-104-CR, Placebo, Livalo.

What is the status of NCT02670434?

NCT02670434 is currently WITHDRAWN.

Last reviewed 2021-05-06 · How we verify

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

NCT02670434 Phase 3 WITHDRAWN

The purpose of this study is to compare the efficacy of NK-104-CR with Placebo and Livalo® on the reduction of LDL-C and to evaluate the safety of NK-104-CR in patients with primary hyperlipidemia or mixed dyslipidemia

Details

Lead sponsor	Kowa Research Institute, Inc.
Phase	Phase 3
Status	WITHDRAWN
Start date	2016-01
Completion	2017-10

Conditions

Hyperlipidemia
Dyslipidemia

Interventions

NK-104-CR
Placebo
Livalo

Primary outcomes

Percent change in LDL-C from baseline — 12 Weeks

Countries

United States